C4 JPM 2025_1.13.25_FINAL.pdf

1、Protein degraded.Disease targeted.Lives transformed.43rdAnnual J.P.Morgan Healthcare Conference January 2025Forward-looking Statements and Intellectual Property2FORWARD-LOOKING STATEMENTSThe following presentation contains forward-looking statements.All statements other than statements of historical

2、 fact are forward-looking statements,which are often indicated by terms such as“anticipate,”“believe,”“could,”“estimate,”“expect,”“goal,”“intend,”“look forward to,”“may,”“plan,”“potential,”“predict,”“project,”“should,”“will,”“would”and similar expressions.These forward-looking statements include,but

3、 are not limited to,statements regarding the therapeutic potential of C4 Therapeutics,Inc.s technology and products.These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties.Among the factors that could cause actual results to differ materially f

4、rom those described or projected herein include uncertainties associated generally with research and development,clinical trials and related regulatory reviews and approvals,as well as the fact that the product candidates that we are developing or may develop may not demonstrate success in clinical

5、trials.Prospective investors are cautioned not to place undue reliance on these forward-looking statements,which speak only as of the date hereof.The forward-looking statements included in this presentation are subject to a variety of risks and uncertainties,including those set forth in our most rec

6、ent and future filings with the Securities and Exchange Commission.Our actual results could vary significantly from those anticipated in this presentation,and our financial condition and results of operations could be materially adversely affected.C4 Therapeutics,Inc.undertakes no obligation to upda